finsmart-news_admin 
Billionaire Stanley Druckenmiller is pouring millions of dollars into two stocks after dumping two of the hottest equities on the market.
The latest 13F filings show Druckenmiller’s Duquesne Family Office sold all Nvidia (NVDA) shares in the third quarter of 2024 and fully exited its entire Palantir (PLTR) position by mid-2025.
Druckenmiller has shifted his focus to healthcare, boosting holdings in Eli Lilly (LLY) to 100,675 shares, valued at about $78.5 million in Q2 2025.
Eli Lilly leads in GLP-1 drugs for weight loss and diabetes, with products like Mounjaro.
Druckenmiller also purchased 549,295 shares of Viking Therapeutics (VKTX), worth around $14.6 million.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
This move reflects a pivot from AI hype to biotech innovation.
Druckenmiller, a legendary investor with a history of bold bets, manages over $4 billion.
